OWEN KATEY EINTERZ sold $250K of ADPT
OWEN KATEY EINTERZ sold 9,615 shares of Adaptive Biotechnologies Corp (ADPT) at $26.00 ($0.25M total) on 2026-08-26.
How this was made
The 30-second read
Why it matters
The director's sale adds modest negative pressure, but the overall impact on ADPT's valuation is limited.
Market read
Primary insider sale provides new information for short‑term traders; limited long‑term effect.
What to watch
Einterz's remaining 78,639 shares still represent a sizable stake, mitigating concern.
Background
SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.
Ticker impact
Director Owen Katey Einterz sold 9,615 shares of Adaptive Biotechnologies for $250K on Aug 26, 2026.
Potential short-term dip of 0.5‑1% as market digests the sale.
Director sales often weigh on investor perception; however, the $250K amount is small for a mid‑cap biotech.
Market effects
Minor negative signal for biotech sector insiders, but unlikely to affect broader sector.
No significant regional effect; confined to US biotech investors.
Limited global relevance; only impacts ADPT shareholders.
Counterpoint
The sale could be routine portfolio rebalancing, not a red flag.
Key entities
- CompanyAdaptive Biotechnologies Corp
US‑listed biotech (ticker ADPT) focused on immune profiling.
- IndividualOwen Katey Einterz
Director of Adaptive Biotechnologies.
